Exhibit 99
GE HealthCare
Recast Unaudited Historical Financial Information Reflecting the Company’s New Reportable Segment Structure

In the second quarter of 2026, we made a strategic change to our executive leadership and to our segments, combining our Imaging and Advanced Visualization Solutions businesses into a new operating and reportable segment, Advanced Imaging Solutions (“AIS”). This change positions the Company to enhance execution, accelerate innovation, and create efficiencies.

Following this organizational change, the Company has three reportable segments: AIS, Pharmaceutical Diagnostics (“PDx”), and Patient Care Solutions (“PCS”), which is aligned with how the Chief Operating Decision Maker reviews the business for the purpose of assessing performance and allocating resources. These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. Our PDx and PCS reportable segments operate as described in the “Business” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

ADVANCED IMAGING SOLUTIONS.

Our AIS segment provides diagnostic, interventional, and digital imaging technologies designed to support clinical decision-making across the care continuum, from screening and diagnosis through treatment and follow-up. The AIS segment has a product portfolio that serves customers across three core areas: Radiology, Specialized Ultrasound, and Procedural Guidance. Radiology was formerly reported as our Imaging business, while Specialized Ultrasound and Procedural Guidance were previously reported in our AVS business. Our products support providers in the delivery of care for a broad spectrum of clinical specialties, including oncology, cardiology, neurology, nuclear medicine, orthopedics, women’s health, pediatrics, and surgery.

Radiology includes the following product lines.
•Computed Tomography (“CT”) scans render 3D anatomical images of structures, such as bone, soft tissue, and air cavities using an X-ray tube that rotates around a patient. The images are used in a wide variety of applications, including the detection of tumors or lesions, blocked blood vessels in the brain, abnormal heart conditions, complex bone fractures, and internal injuries from trauma. Our comprehensive CT portfolio includes multi-purpose and specialty scanners.
•Magnetic Resonance (“MR”) is a non-invasive imaging technology that produces detailed anatomical images of almost every internal structure in the human body, such as the brain, spinal cord, heart, breast, kidneys, muscles, ligaments, and tendons. MR can also be used for functional imaging, and it is well-suited for disease detection, diagnosis, and treatment monitoring of a variety of conditions, including stroke, cancer, trauma, aneurysm, multiple sclerosis, cardiomyopathy, and congenital disorders. Our MR portfolio includes scanners for a range of clinical capabilities through different bore sizes, magnetic field strengths, and scalable platforms.
•Molecular Imaging (“MI”) enables the visualization, characterization, and quantification of functional processes taking place at the cellular and subcellular levels within patients. The images produced by MI systems allow clinicians to study the cellular and molecular pathways and mechanisms of disease in patients. We offer a complete MI solution from cyclotrons, chemistry synthesis, positron emission tomography (“PET”), CT, single-photon emission computed tomography, PET/MR, and nuclear medicine to advanced digital and AI-enabled solutions. Our MI team works closely with the PDx segment and their innovations and collaborations with pharmaceutical companies.
•Solutions for Enterprise Imaging provides a portfolio of cloud-enabled, AI-powered software that enables healthcare organizations to capture, manage, and integrate medical imaging and related clinical data across the enterprise. These solutions support radiology, cardiology, and other imaging specialties by streamlining workflows, improving clinician productivity, and enhancing care coordination across hospital, outpatient, and ambulatory settings. The portfolio is designed to evolve over time through software upgrades and new capabilities, helping customers address workforce challenges and improve patient outcomes.
•Women’s Health products use X-ray technology to help clinicians screen for and diagnose breast cancer as well as bone and metabolic diseases in women. The product portfolio includes imaging and biopsy positioning systems designed to image the breast and dual energy X-ray absorptiometry scanners designed to image bones with low mineral density.
•X-ray systems are used by clinicians to perform first-line diagnostic imaging examinations of anatomical structures in the body, such as bones, lungs, and the gastrointestinal tract. Our X-ray product portfolio includes systems for three distinct clinical situations: fixed room radiography products installed in hospitals and imaging centers; mobile radiography products used for bedside or other point-of-care imaging needs; and fluoroscopy products installed in hospitals for dynamic or “moving” X-ray imaging in applications like gastrointestinal examinations.

1






Procedural Guidance includes the following product lines.
•CardioVascular and Interventional Solutions provides clinicians with innovative solutions that enhance diagnoses, intervention, treatment, and monitoring in therapeutic areas such as cardiology in the catheterization labs, peripheral vascular, neurovascular, interventional radiology, and oncology. Our integrated portfolio of ultrasound systems for assessing cardiac structure and function, alongside advanced real-time X-ray imaging systems, combines innovative imaging technology, intelligent workflows, and ergonomic design to help healthcare providers deliver care with greater confidence and efficiency. Together, these solutions support image-guided therapy across the full spectrum of interventional procedures.
•Surgical Innovations products are used in the procedural environment and include a broad portfolio of advanced mobile surgical C-arms that meet clinical needs for surgical imaging and are designed to be easily maneuverable in operating rooms and adaptable for various surgical procedures. Surgical visualization and guidance technology expands the use of ultrasound beyond diagnostics to provide real-time information during procedures to help guide interventions and navigate inside the human body.

Specialized Ultrasound includes the following product lines.
•Comprehensive Care Ultrasound includes systems that produce images to support precise screening, diagnosis, monitoring, and treatment across the whole body, including liver, thyroid, kidney, breast, vascular, and transcranial applications. These systems include point-of-care and handheld ultrasound devices to support clinical decision-making throughout various care pathways in diverse sites of care. Our systems combine high image quality with comprehensive clinical tools including measurement quantification, workflow automation, cross-modality networking, real-time and AI-enabled scan guidance, and cloud-based technologies with versatility, accessibility, and portability required to deliver care.
•Women’s Health Ultrasound provides systems to support obstetrics, gynecology, and reproductive medicine. These care areas require specially designed ultrasound products that account for patient comfort and workflow constraints to enable practitioners to provide higher-quality screening, exams, and procedural care, and give clinicians images with the clarity and definition they need to focus on early detection and intervention.

Tables throughout this document are presented in millions of U.S. dollars unless otherwise stated and certain columns and rows may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.

The tables below reflect our unaudited historical financial results recast to conform to the new segment structure.

Total Revenues by SegmentFor the three months ended
Unaudited
March 31, 2026
AIS:
Radiology$2,299 
Procedural Guidance719 
Specialized Ultrasound622 
Total AIS3,640 
Total PDx770 
PCS:
Monitoring Solutions519 
Life Support Solutions185 
Total PCS704 
Other(1)
18 
Total revenues$5,131 
(1) Financial information not presented within the reportable segments, shown within the Other category, represents HealthCare Financial Services (“HFS”), which does not meet the definition of an operating segment.

2

Total Revenues by SegmentFor the three months endedFor the year ended
Unaudited
March 31, 2025June 30, 2025September 30, 2025December 31, 2025December 31, 2025
AIS:
Radiology$2,140 $2,204 $2,349 $2,552 $9,245 
Procedural Guidance641 660 662 789 2,752 
Specialized Ultrasound598 630 638 735 2,601 
Total AIS3,379 3,493 3,649 4,077 14,599 
Total PDx632 729 749 790 2,900 
PCS:
Monitoring Solutions556 578 544 577 2,256 
Life Support Solutions197 200 187 247 831 
Total PCS753 778 731 825 3,086 
Other(1)
13 6 15 7 40 
Total revenues$4,777 $5,007 $5,143 $5,698 $20,625 
(1) Financial information not presented within the reportable segments, shown within the Other category, represents HFS, which does not meet the definition of an operating segment.

Total Revenues by SegmentFor the three months endedFor the year ended
UnauditedMarch 31, 2024June 30, 2024September 30, 2024December 31, 2024December 31, 2024
AIS:
Radiology$2,062 $2,171 $2,229 $2,393 $8,855 
Procedural Guidance651 668 647 744 2,711 
Specialized Ultrasound576 581 569 696 2,420 
Total AIS3,289 3,419 3,445 3,833 13,986 
Total PDx599 639 625 646 2,508 
PCS:
Monitoring Solutions527 538 556 574 2,194 
Life Support Solutions220 235 223 253 931 
Total PCS747 772 779 827 3,125 
Other(1)
15 9 15 13 52 
Total revenues$4,650 $4,839 $4,863 $5,319 $19,672 
(1) Financial information not presented within the reportable segments, shown within the Other category, represents HFS, which does not meet the definition of an operating segment.

Significant Expenses by SegmentFor the three months ended
March 31, 2026
AIS:
Cost of sales$2,204 
Other segment items(1)
957 
Total AIS
$3,161 
PDx:
Cost of sales$406 
Other segment items(1)
167 
Total PDx$573 
PCS:
Cost of sales$481 
Other segment items(1)
213 
Total PCS$694 
(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.

3

Significant Expenses by SegmentFor the three months endedFor the year ended
March 31, 2025June 30, 2025
September 30, 2025
December 31, 2025
December 31, 2025
AIS:
Cost of sales$1,951 $2,106 $2,218 $2,452 $8,727 
Other segment items(1)
968 932 920 984 3,804 
Total AIS
$2,919 $3,039 $3,138 $3,436 $12,532 
PDx:
Cost of sales$294 $371 $384 $400 $1,450 
Other segment items(1)
133 144 145 156 579 
Total PDx$428 $516 $529 $556 $2,028 
PCS:
Cost of sales$481 $507 $503 $538 $2,028 
Other segment items(1)
224 212 201 212 849 
Total PCS$705 $719 $703 $750 $2,877 
(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.

Significant Expenses by SegmentFor the three months endedFor the year ended
March 31, 2024June 30, 2024September 30, 2024December 31, 2024December 31, 2024
AIS:
Cost of sales$1,936 $2,004 $1,995 $2,173 $8,108 
Other segment items(1)
931 952 932 984 3,798 
Total AIS$2,867 $2,956 $2,927 $3,157 $11,906 
PDx:
Cost of sales$295 $314 $312 $314 $1,236 
Other segment items(1)
126 125 120 119 490 
Total PDx$421 $439 $432 $433 $1,725 
PCS:
Cost of sales$460 $480 $486 $505 $1,930 
Other segment items(1)
206 215 211 216 848 
Total PCS$666 $694 $697 $721 $2,778 
(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.

4

Segment EBIT
For the three months ended
Unaudited
March 31, 2026
Segment EBIT
AIS$479 
PDx 197 
PCS 10 
Other(1)
5 
691 
Restructuring costs(49)
Acquisition and disposition-related benefits (charges)
(35)
Gain (loss) on business and asset dispositions
— 
Spin-Off and separation costs(2)
Amortization of acquisition-related intangible assets(47)
Investment revaluation gain (loss)(8)
Interest and other financial charges – net(96)
Non-operating benefit income (costs)51 
Income before income taxes$505 
(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS, which does not meet the definition of an operating segment.


Segment EBIT
For the three months endedFor the year ended
Unaudited
March 31, 2025June 30, 2025September 30, 2025December 31, 2025December 31, 2025
Segment EBIT
AIS$460 $455 $512 $641 $2,067 
PDx 205 213 220 234 872 
PCS 48 60 27 74 209 
Other(1)
2 1 2 2 7 
715 729 761 950 3,155 
Restructuring costs(22)(18)(31)(48)(120)
Acquisition and disposition-related benefits (charges)
(8)(7)(9)(15)(39)
Gain (loss) on business and asset dispositions
10 (5)— — 5 
Spin-Off and separation costs(24)(5)(6)(3)(38)
Amortization of acquisition-related intangible assets(35)(40)(41)(41)(156)
Investment revaluation gain (loss)92 (1)4 16 112 
Interest and other financial charges – net(110)(113)(111)(105)(440)
Non-operating benefit income (costs)74 73 75 66 288 
Income before income taxes$692 $613 $643 $820 $2,768 
(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS, which does not meet the definition of an operating segment.

5

Segment EBITFor the three months endedFor the year ended
UnauditedMarch 31, 2024June 30, 2024September 30, 2024December 31, 2024December 31, 2024
Segment EBIT
AIS$422 $463 $518 $676 $2,080 
PDx 178 200 193 212 783 
PCS 81 78 82 106 347 
Other(1)
(1)1 1 — 2 
681 742 795 994 3,211 
Restructuring costs(40)(29)(22)(30)(120)
Acquisition and disposition-related benefits (charges)
— 3 4 (9)(3)
Gain (loss) on business and asset dispositions
— — (1)— — 
Spin-Off and separation costs(60)(67)(56)(68)(251)
Amortization of acquisition-related intangible assets(31)(35)(34)(36)(137)
Investment revaluation gain (loss)(20)(6)(1)4 (22)
Interest and other financial charges – net(122)(131)(130)(121)(504)
Non-operating benefit income (costs)102 101 102 100 406 
Income before income taxes$512 $578 $658 $834 $2,581 
(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS, which does not meet the definition of an operating segment.

Depreciation and Amortization by Segment
For the three months ended
March 31, 2026
AIS
$72 
PDx 20 
PCS 13 

Depreciation and Amortization by Segment
For the three months endedFor the year ended
March 31, 2025June 30, 2025
September 30, 2025
December 31, 2025
December 31, 2025
AIS
$75 $75 $73 $73 $297 
PDx 12 17 19 19 66 
PCS 13 13 14 13 53 

Depreciation and Amortization by Segment
For the three months endedFor the year ended
March 31, 2024June 30, 2024September 30, 2024December 31, 2024
December 31, 2024
AIS
$86 $83 $82 $77 $327 
PDx 16 15 12 12 55 
PCS 15 14 13 14 55 

NON-GAAP FINANCIAL MEASURES

The non-GAAP financial measures presented in this Exhibit 99 are supplemental measures of our performance that we believe will help investors understand our results of operations, and assess our future prospects. When read in conjunction with our U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in our underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions.


6

We report Organic revenue and Organic revenue growth rate to provide management and investors with additional understanding and visibility into the underlying revenue trends of our established, ongoing operations, as well as provide insights into overall demand for our products and services. To calculate these measures, we exclude the effect of acquisitions, dispositions, and foreign currency rate fluctuations.

Organic Revenue*
For the three months ended March 31
Unaudited
20262025% change
AIS revenues    
$3,640$3,3797.7%
Less: Acquisitions(1)    
11—
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
114—
AIS Organic revenue*
$3,515$3,3794.0%
PDx revenues    
$770$63221.7%
Less: Acquisitions(1)    
501
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
28—
PDx Organic revenue*    
$692$6319.7%
PCS revenues    
$704$753(6.5)%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
12—
PCS Organic revenue*    
$692$753(8.1)%
Other revenues    
$18$1337.7%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
——
Other Organic revenue*    
$18$1337.7%
Total revenues    
$5,131$4,7777.4%
Less: Acquisitions(1)    
601
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
155—
Organic revenue*    
$4,916$4,7762.9%
(1)
Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction, excluding the impact of Foreign currency exchange already captured in lines elsewhere.
(2)
Represents revenues attributable to dispositions for the four quarters preceding the disposition date.
















____________________
*Non-GAAP Financial Measure
7

Organic Revenue*
For the three months ended December 31For the year ended December 31
Unaudited
20252024% change20252024% change
AIS revenues    
$4,077$3,8336.4%$14,599$13,9864.4%
Less: Acquisitions(1)    
1—15—
Less: Dispositions(2)    
————
Less: Foreign currency exchange    
56—65—
AIS Organic revenue*
$4,020$3,8334.9%$14,519$13,9863.8%
PDx revenues    
$790$64622.3%$2,900$2,50815.6%
Less: Acquisitions(1)    
5111544
Less: Dispositions(2)    
————
Less: Foreign currency exchange    
13—21—
PDx Organic revenue*    
$726$64512.7%$2,724$2,5048.8%
PCS revenues    
$825$827(0.3)%$3,086$3,125(1.2)%
Less: Acquisitions(1)    
————
Less: Dispositions(2)    
————
Less: Foreign currency exchange    
7—7—
PCS Organic revenue*    
$818$827(1.1)%$3,079$3,125(1.5)%
Other revenues    
$7$13(48.1)%$40$52(23.0)%
Less: Acquisitions(1)    
————
Less: Dispositions(2)    
————
Less: Foreign currency exchange    
————
Other Organic revenue*    
$7$13(48.1)%$40$52(23.3)%
Total revenues    
$5,698$5,3197.1%$20,625$19,6724.8%
Less: Acquisitions(1)    
5211694
Less: Dispositions(2)    
————
Less: Foreign currency exchange    
75—94—
Organic revenue*    
$5,571$5,3184.8%$20,363$19,6673.5%
(1)
Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.
(2)
Represents revenues attributable to dispositions for the four quarters preceding the disposition date.
















____________________
*Non-GAAP Financial Measure
8

Organic Revenue*
For the three months ended September 30
Unaudited
20252024% change
AIS revenues    
$3,649$3,4455.9%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
41—
AIS Organic revenue*
$3,608$3,4454.7%
PDx revenues    
$749$62519.8%
Less: Acquisitions(1)    
511
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
15—
PDx Organic revenue*    
$683$6239.6%
PCS revenues    
$731$779(6.2)%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
4—
PCS Organic revenue*    
$727$779(6.7)%
Other revenues    
$15$15(1.5)%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
——
Other Organic revenue*    
$14$15(3.1)%
Total revenues    
$5,143$4,8635.8%
Less: Acquisitions(1)    
511
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
60—
Organic revenue*    
$5,033$4,8623.5%
(1)
Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.
(2)
Represents revenues attributable to dispositions for the four quarters preceding the disposition date.
















____________________
*Non-GAAP Financial Measure
9

Organic Revenue*
For the three months ended June 30
Unaudited
20252024% change
AIS revenues    
$3,493$3,4192.2%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
25—
AIS Organic revenue*
$3,468$3,4191.4%
PDx revenues    
$729$63914.1%
Less: Acquisitions(1)    
532
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
7—
PDx Organic revenue*    
$669$6375.0%
PCS revenues    
$778$7720.8%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
3—
PCS Organic revenue*    
$775$7720.4%
Other revenues    
$6$9(39.2)%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
——
Other Organic revenue*    
$6$9(40.6)%
Total revenues    
$5,007$4,8393.5%
Less: Acquisitions(1)    
532
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
36—
Organic revenue*    
$4,917$4,8371.7%
(1)
Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.
(2)
Represents revenues attributable to dispositions for the four quarters preceding the disposition date.
















____________________
*Non-GAAP Financial Measure
10

Organic Revenue*
For the three months ended March 31
Unaudited
20252024% change
AIS revenues    
$3,379$3,2892.7%
Less: Acquisitions(1)    
14—
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
(57)—
AIS Organic revenue*
$3,423$3,2894.1%
PDx revenues    
$632$5995.6%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
(14)—
PDx Organic revenue*    
$646$5997.9%
PCS revenues    
$753$7470.8%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
(7)—
PCS Organic revenue*    
$760$7471.7%
Other revenues    
$13$15(11.4)%
Less: Acquisitions(1)    
——
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
——
Other Organic revenue*    
$13$15(10.0)%
Total revenues    
$4,777$4,6502.7%
Less: Acquisitions(1)    
14—
Less: Dispositions(2)    
——
Less: Foreign currency exchange    
(78)—
Organic revenue*    
$4,842$4,6504.1%
(1)
Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.
(2)
Represents revenues attributable to dispositions for the four quarters preceding the disposition date.
















____________________
*Non-GAAP Financial Measure
11